Logo

Roche Launches $2.2B Debt Tender Offer

Oct 30, 2014 | staff reporter

NEW YORK (GenomeWeb) – Roche announced late yesterday that it has commenced a $2.2 debt tender offer.

The Swiss pharmaceuticals, diagnostics, and research products giant said that it launched an offer to purchase for cash the 5.25 percent Senior Notes due 2035 issued by its Genentech subsidiary and the 7 percent Senior Notes due 2039 issued by Roche Holdings.

The Genentech Senior Notes have a principal outstanding amount of $500 million, while the Roche Holdings Senior Notes have a principal outstanding amount of $2.5 billion. It listed the Genentech notes as having a higher acceptance priority level.

The offer is set to expire on Nov. 26, 2014, unless Roche terminates or extends the offer before that time.

Filed under

Roche
Genentech
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.